Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety

Introduction: Most chronic hepatitis B (CHB) patients in China are primitively treated with a combination of lamivudine (LAM) and adefovir dipivoxil (ADV). Although antiviral resistance can be avoided with this combination therapy, using it can have harmful side effects related to ADV, specifically...

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Jiang-Shan, Zhang, Xiao-Lin, Lu, Ying-Feng, Chen, Jian-Yang, Zhang, Yi-Min, Jia, Hong-Yu, Zhang, Zhe, Yang, Yi-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332476/
https://www.ncbi.nlm.nih.gov/pubmed/30662324
http://dx.doi.org/10.7150/ijms.28700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332476/
https://www.ncbi.nlm.nih.gov/pubmed/30662324
http://dx.doi.org/10.7150/ijms.28700

Ejemplares similares